Please check your internet connection and try again.
# Durveqtix (fidanacogene elaparvovec-dzkt)
## Overview
Durveqtix is an adeno-associated virus (AAV) vector-based gene therapy designed to deliver a functional copy of the *F9* gene to liver cells. It enables the production of Factor IX (FIX) in patients with Hemophilia B, potentially eliminating the need for routine prophylactic factor replacement therapy.
## Primary Indications
Treatment of adults (18 years or older) with moderately severe to severe Hemophilia B who are currently using Factor IX prophylaxis therapy or have a current or historical life-threatening hemorrhage or repeated, serious spontaneous bleeding episodes.
## Adult Dosing
The recommended dose is a single intravenous infusion of **5 x 10¹¹ vector genomes per kilogram (vg/kg) of body weight.**
## Pediatric Dosing
Safety and efficacy have not been established in pediatric patients (younger than 18 years). Use in this population is not indicated.
## Dose Adjustments
* **Renal/Hepatic Impairment:** No formal clinical studies have been conducted in patients with renal or hepatic impairment.
* **Adjustments:** No dose adjustments are permitted. The drug is administered as a one-time infusion.
## Contraindications
* Known hypersensitivity to fidanacogene elaparvovec-dzkt or any component of the formulation.
* Presence of neutralizing antibodies to the AAVRh74 capsid (determined by a validated clinical trial assay).
## Adverse Effects
* **Most Common:** Elevation in liver enzymes (ALT/AST), infusion-related reactions, headache, nausea, and fatigue.
* **Serious:** Potential for hepatotoxicity requiring immunosuppressant therapy (corticosteroids).
* **Long-term:** Theoretical risk of insertional mutagenesis, though not observed in clinical trials to date.
## Key Drug Interactions
* **Immunosuppressants:** Systemic corticosteroids (e.g., prednisone or equivalent) are typically required following infusion to manage or prevent capsid-specific immune responses and associated liver enzyme elevations.
* **Hepatotoxic Agents:** Use caution with concomitant medications that may contribute to liver injury, as this may complicate the monitoring of post-infusion liver enzyme elevations.
## Monitoring
* **Liver Enzymes:** Monitor ALT/AST levels weekly for at least the first 3 to 4 months post-infusion.
* **Factor IX Activity:** Monitor FIX activity levels periodically to assess response and the need for hemostatic coverage.
* **Malignancy:** Long-term follow-up (up to 15 years) is required to monitor for the theoretical risk of malignancy.
## Clinical Pearls
* **Pre-infusion Screening:** Patients must be screened for pre-existing neutralising antibodies to the AAVRh74 capsid prior to therapy.
* **Immunosuppression:** Prepare to initiate a prolonged taper of oral corticosteroids at the first sign of elevated liver enzymes to prevent the loss of transgene expression.
* **Post-Therapy:** Patients may continue to experience "breakthrough" bleeds during the initial weeks/months post-infusion; factor concentrates should remain available for emergency use.
* **Uncertainty:** Durveqtix is a novel therapy; the durability of Factor IX expression beyond 5 years in humans remains unknown.
***
*Disclaimer: This information is for educational purposes only. Always verify dosing, contraindications, and administration protocols against the official FDA-approved prescribing information (PI) or local institutional guidelines before prescribing or administering gene therapy products.*
